Suven Life Sciences to Showcase CNS Clinical Pipeline and Partnering Strategies at BIO 2026
Hyderabad, India, June 22, 2026 — Suven Life Sciences Limited, a clinical-stage biopharmaceutical company focused on discovering innovative treatments for Central Nervous System (CNS) disorders, has announced its participation in the BIO International Convention 2026. The event takes place from June 22 to 25, 2026, in San Diego, USA, and is recognized as one of the world's largest Biotechnology Partnering Conferences.Suven Life Sciences will host Delegates, Investors, and potential collaborators from Big Pharma and Biotech companies at Booth # 6154. The company plans to showcase its differentiated CNS portfolio, which includes late-stage clinical assets targeting critical unmet medical needs such as Agitation in Dementia of Alzheimer's Type, Major Depressive Disorder, Narcolepsy, and Cognitive Impairment associated with Parkinson's disease.
The primary goal is to engage with global pharmaceutical and biotechnology companies to explore potential partnering strategies, out-licensing opportunities, and co-development initiatives for the company’s clinical candidates through 62 pre-scheduled meetings during the four days of BIO-2026.
The Suven delegation at BIO-2026 includes senior leadership from both the Management team and Research, including Venkat Jasti, Chairman and Managing Director; Ramakrishna Nirogi, President and Chief Scientific Officer; Anil Shinde, Vice President, Drug Chemistry; Pradeep Jayarajan, Vice President, Drug Biology; Vijay Benade, Associate Vice President, Drug Metabolism & Pharmacokinetics; and Satish Jetta, Associate Vice President, Quality Assurance & Regulatory.
Mr. Venkat Jasti, Chairman and Managing Director of Suven Life Sciences, stated that BIO-2026 offers a significant opportunity to highlight the advancements in their clinical pipeline. He noted that positive Phase 2b results for Ropanicant in major depressive disorder, promising Phase-1 data for SUVN-I6107, continued progress of Phase-3 programs, Masupirdine for agitation in dementia of Alzheimer's type, and Samelisant (AWAKE study) for narcolepsy underscore the depth and maturity of their portfolio. The company looks forward to exploring strategic partnerships that can accelerate the development and commercialization of these assets.
Suven’s Differentiated CNS Clinical Portfolio
Suven Life Sciences holds all intellectual property rights for its assets in all major markets. The specialized focus on CNS disorders is supported by a robust pipeline, as detailed below:| Drug Candidate | Mechanism / Status | Key Indication & Findings |
|---|---|---|
| Ropanicant (SUVN-911) | α4β2 receptor antagonist; Phase-2b trial. | Novel antidepressant candidate for Major Depressive Disorder (MDD). Reported positive topline results from the Phase-2b clinical Proof-of-Concept trial, with a global Phase-3 study set to start in H1-2027. |
| Masupirdine (SUVN-502) | 5-HT6 Receptor antagonist; Global Phase-3 underway. | A differentiated, non-sedative approach for transforming Alzheimer's agitation management, delivering dual impact on behavioral stabilization and cognition. Topline results are expected in Q2-2027. |
| Samelisant (SUVN-G3031) | H3 inverse agonist; Global Phase 3 study initiated. | Designed as a non-controlled, non-stimulant agent for narcolepsy. The global Phase 3 study is underway, with topline results expected in Q2-2028. |
| Usmarapride (SUVN-D4010) | 5-HT4 Receptor Partial Agonist; Phase 1 complete. | A novel approach for cognitive disorders. The compound proved safe and well tolerated in Phase 1, with a Phase 2 study planned. |
| SUVN-I6107 | Muscarinic M1 true positive allosteric modulator (PAM); Phase 1 completed. | Designed for the potential treatment of cognitive disorders. Demonstrated favorable pharmacokinetics and safety in a recently completed Phase-1 trial, indicating enhanced alertness and information processing. |
SUVEN Stock Price Movement
As of 10:31 AM, shares of Suven Life Sciences Limited are slipping by 1.01%, shedding ₹2.70 as they trade at ₹265.5. The stock has moved within a wide intraday range, which saw it rebound from a low of ₹263.25 up to a high of ₹277.15.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: